Brief: Oramed Pharmaceuticals On March 18 Entered Into An At Market Offering Agreement

Oramed Pharmaceuticals

18/03/2024 21:52

March 18 (Reuters) - Oramed Pharmaceuticals Inc
 ORMP.O :
    * ORAMED PHARMACEUTICALS INC -  ON MARCH 18 ENTERED INTO AN
AT
MARKET OFFERING AGREEMENT
    * ORAMED PHARMACEUTICALS - PURSUANT TO AGREEMENT MAY ISSUE
AND
SELL SHARES OF COMMON STOCK HAVING MAXIMUM AGGREGATE OFFERING
PRICE OF UP TO $75 MILLION
    * ORAMED PHARMACEUTICALS - ON MARCH 12 DELIVERED WRITTEN
NOTICE TO
CANTOR FITZGERALD & CO. TO TERMINATE CERTAIN CONTROLLED EQUITY
OFFERING AGREEMENT
    * ORAMED PHARMACEUTICALS - WRITTEN NOTICE TO TERMINATE
CERTAIN
CONTROLLED EQUITY OFFERING AGREEMENT, DATED SEPT 1, 2021
EFFECTIVE AS OF MARCH 17, 2024
    * ORAMED PHARMACEUTICALS - PRIOR TO ITS TERMINATION,
RECEIVED
ABOUT $26.25 MILLION IN NET PROCEEDS FROM SALES OF COMMON STOCK
PURSUANT TO CANTOR AGREEMENT
    * ORAMED PHARMACEUTICALS INC - NO TERMINATION PENALTIES WERE
INCURRED BY COMPANY IN CONNECTION WITH TERMINATION OF CANTOR
AGREEMENT.

Source text for Eikon:  ID:n0001213900-24-023571 
Further company coverage:  ORMP.O 

 ((Reuters.Briefs@thomsonreuters.com;))